医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Meiji Seika Pharma: Adcock Ingram Pharma Private Limited Completes Construction of a New Manufacturing Facility in India to Enhance its CMO Business

2023年05月31日 PM03:00
このエントリーをはてなブックマークに追加


 

TOKYO

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo Japan, President and Representative Director: Daikichiro Kobayashi) announces that Adcock Ingram Pharma Private Limited (Headquarters: Bengaluru India, Managing Director: Y.A. Chowdary), an affiliated company of Medreich Limited (Headquarters: Bengaluru India, Managing Director: Pankaj Garg), has completed construction of a new manufacturing facility in Bengaluru, India, to enhance its production capacity of the contract manufacturing organization (CMO) business.

Adcock Ingram Pharma Private Limited, established in 2021, is a wholly-owned subsidiary of Adcock Ingram Limited that is a joint venture between Adcock Ingram Holdings Ltd., in South Africa, and Medreich Limited.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230530005041/en/

Image of the new manufacturing facility (Photo: Business Wire)

Image of the new manufacturing facility (Photo: Business Wire)

The new manufacturing facility has three floors above ground, a total floor area of 7,878 m2, having an annual production capacity of 750 million tablets, 75 million sachets, and 4 million bottles, so that Adcock Ingram Pharma Private Limited can manufacture and supply pharmaceutical products not only for the Adcock Ingram Group in South Africa, but also for other clients.

The Meiji Group’s Pharmaceutical Segment, in its “2023 Medium-Term Business Plan”, has set an agenda to “Expand CMO/CDMO business” in its business strategies, in which Medreich Limited and Adcock Ingram Limited are regarded as the core companies of the CMO business. We will continue to optimize our production bases in Japan and overseas to strengthen our production system and establish the one for stable supply of highly reliable pharmaceuticals and contribute to improving access to pharmaceuticals for people over the world.

*Overview of the new manufacturing facility

(1) Location

41/42, Bommasandra Industrial Area, Anekal Taluk, Bangalore 560 099, India

(2) Site area

Approx. 8,000m2

(3) Total floor area

Approx. 7,878m2

(4) Construction costs

Approx. JPY 2.21 billion

(5) Production capacity (annual)

Tablets: 750 million tablets
Sachets: 75 million sachets
Bottles: 4 million bottles

(6) Start of commercial productions

January 2024

*About Adcock Ingram Holdings Ltd.

Adcock Ingram Holdings Ltd. is a leading South African pharmaceutical manufacturer, founded in 1891. Adcock Ingram Holdings Ltd. manufactures, markets and distributes a wide range of healthcare and consumer products, and is a leading supplier to both the private and public sectors of the market.

*: For further information, please visit the website at: www.adcock.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20230530005041/en/

CONTACT

Contact to

Meiji Seika Pharma Co., Ltd.

Kensuke Hata

General Manager

Medreich Operations Dept.

Telephone: +81-3-3273-6030

E-mail : pr-pharma@meiji.com

同じカテゴリーの記事 

  • Heuron Gets FDA Green Light for Stroke Triage and Notification Solution
  • iCell Gene Therapeutics Announces Positive Clinical Data from Investigator Initiated Phase 1 Trial Evaluating BCMA-CD19 Compound CAR in Patients with Systemic Lupus Erythematosus/Lupus Nephritis Published in Annals of the Rheumatic Diseases
  • Galderma Launches Restylane® VOLYME™ in China – One of the World’s Fastest Growing Aesthetics Markets
  • Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia
  • Otsuka to Terminate Development of AVP-786